Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Group B Streptococcus surface proteins are a diverse group of cell wall-anchored molecules expressed on the outer membrane of *Streptococcus agalactiae* that play critical roles in bacterial pathogenesis. These include well-characterized adhesins such as fibrinogen-binding proteins FbsA/B/C, serine-rich repeat glycoproteins Srr1/Srr2, laminin-binding protein Lmb, C5a peptidase ScpB, fibronectin-binding protein SfbA, and immunogenic bacterial adhesin BibA. Other notable members include the S-protein homologs and R-like antigens such as R3 and BPS. These proteins mediate adherence to host tissues and extracellular matrix components—key steps in colonization and invasion—and contribute to biofilm formation. They also interact with host immune defenses by modulating complement activation or binding inhibitory receptors on leukocytes. The diversity among these antigens complicates vaccine development due to strain-specific expression patterns. GBS surface proteins are considered important therapeutic targets for vaccine development because they can elicit protective immune responses against infection by promoting opsonophagocytosis or blocking adhesion/invasion pathways. However, no small-molecule drugs specifically targeting these molecules have been developed yet. ### Additional Notes - **Specificity**: The term "Group B streptococcus surface protein" is broad and refers collectively to several distinct molecular entities rather than a single defined receptor. - **Therapeutic Target**: True—these molecules are considered potential targets mainly for vaccines. - **Molecular Classification**: While not strictly receptors/enzymes/transporters/etc., they function primarily as virulence factors/adhesins. - **Disease Role**: Primarily involved in infection caused by Group B Streptococcus. - **Interacting Drugs/Mechanism/Biomarkers**: Currently none established beyond experimental antibody/vaccine approaches. If you require information on a specific member within this group (e.g., FbsA or R3), please specify so that more precise details can be provided.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Group B Streptococcus surface protein (GBS surface protein).